EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>
Edap TMS SA, a global leader in robotic energy-based therapies, announced on September 8, 2025, that the French Ministry of Health has granted reimbursement for the High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer treatment in France. This approval covers the use of the Focal One Robotic HIFU procedure under France's national universal health system, "Sécurité Sociale," for eligible patients as a primary treatment for localized prostate cancer and as a salvage treatment following radiotherapy. This reimbursement milestone, effective from September 1, 2025, enhances patient access to non-invasive prostate cancer management in France. The decision follows the positive findings of the HIFI Study, sponsored by the French Urology Association, and is expected to facilitate similar approvals across Europe.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126766-en) on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.